Linked Life Data

10528788

Source:http://linkedlifedata.com/resource/pubmed/id/10528788

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1999-11-30
pubmed:abstractText
The emergence of MRSA in the 1960s coincided with the introduction of fusidic acid. Since that time, the antibiotic has been widely used against this organism, both in the 1960s and 1970s and against the more modern multi-resistant version of the 1980s and 1990s. Although showing potent in vitro activity, experimental in vivo and in vitro investigations have demonstrated disappointing results. Clinical efficacy has been demonstrated in a series of small studies and case reports, particularly when fusidic acid is used in combination for the treatment of MRSA carriage. Given the widespread use of fusidic acid against MRSA, published evidence supporting its efficacy is limited and does not support the use of the agent as monotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0924-8579
pubmed:author
pubmed:issnType
Print
pubmed:volume
12 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S67-71
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus.
pubmed:affiliation
Department of Infectious Diseases, Infection Control and Sexual Health, Princess Alexandra Hospital, Brisbane, Qld, Australia. bym@health.qld.gov.au
pubmed:publicationType
Journal Article, In Vitro, Review